Lumacaftor-d4

• CAT Number: S000229
• CAS Number: 2733561-44-7
• Molecular Formula: C24H14D4F2N2O5
• Molecular Weight: 456.43
• Purity: ≥95%
• IUPAC Name: 3-[3-methyl-6-[[2,2,3,3-tetradeuterio-1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]pyridin-2-yl]benzoic acid
• InChI: InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)/i9D2,10D2
• InChIKey: UFSKUSARDNFIRC-YQUBHJMPSA-N
• SMILES: [2H]C1(C(C1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=NC(=C(C=C4)C)C5=CC(=CC=C5)C(=O)O)([2H])[2H])[2H]

Lumacaftor-d4 (CAS: 2733561-44-7), a premium pharmaceutical research compound designed for advanced cystic fibrosis studies. As a deuterated analog of Lumacaftor, it offers enhanced stability and improved pharmacokinetic properties. Lumacaftor-d4 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for cystic fibrosis and related conditions. Trusted by leading laboratories, Lumacaftor-d4 is your go-to solution for cutting-edge cystic fibrosis research. Unlock new possibilities in cystic fibrosis treatment with Lumacaftor-d4, where innovation meets reliability.

Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-232.
[Content Brief]